Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

Next Previous
X
Search
Trial Profile

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Everolimus; Fludeoxyglucose F-18
  • Indications Bronchial cancer; Carcinoid tumour; Large cell carcinoma; Lung cancer; Neuroendocrine tumours
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 May 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
    • 25 May 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.
    • 30 Jun 2022 Status changed from suspended to recruiting, according to a Novartis media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top